Coherus Oncology, Inc.
CHRS
$0.7472
-$0.0204-2.66%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 197.50M | 192.21M | 229.59M | 233.38M | 227.12M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 197.50M | 192.21M | 229.59M | 233.38M | 227.12M |
| Cost of Revenue | 85.62M | 84.41M | 135.12M | 147.08M | 143.56M |
| Gross Profit | 111.88M | 107.80M | 94.47M | 86.30M | 83.56M |
| SG&A Expenses | 130.53M | 134.14M | 147.14M | 158.02M | 167.99M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 305.37M | 311.83M | 377.07M | 403.89M | 411.66M |
| Operating Income | -107.88M | -119.63M | -147.49M | -170.51M | -184.54M |
| Income Before Tax | -121.77M | -142.40M | -171.36M | -200.63M | -230.58M |
| Income Tax Expenses | -- | -- | 0.00 | -380.00K | -380.00K |
| Earnings from Continuing Operations | -121.77 | -142.40 | -171.36 | -200.25 | -230.20 |
| Earnings from Discontinued Operations | -9.17M | 170.91M | 170.91M | 170.91M | 170.91M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -130.94M | 28.51M | -450.00K | -29.34M | -59.29M |
| EBIT | -107.88M | -119.63M | -147.49M | -170.51M | -184.54M |
| EBITDA | -103.06M | -114.35M | -142.18M | -165.85M | -180.19M |
| EPS Basic | -1.13 | 0.27 | -0.01 | -0.32 | -0.70 |
| Normalized Basic EPS | -1.51 | -1.57 | -0.79 | -0.98 | -1.28 |
| EPS Diluted | -1.16 | 0.24 | -0.01 | -0.33 | -0.71 |
| Normalized Diluted EPS | -1.51 | -1.57 | -0.79 | -0.98 | -1.28 |
| Average Basic Shares Outstanding | 461.31M | 458.20M | 454.27M | 436.80M | 409.25M |
| Average Diluted Shares Outstanding | 461.31M | 458.20M | 454.27M | 436.80M | 409.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |